Photo by nci from unsplash
Approximately 20% of patients with a recurrently poor platelet transfusion increment show human leukocyte antigen (HLA) alloantibodies. The aim of this study was to analyse the impact of mean fluorescence… Click to show full abstract
Approximately 20% of patients with a recurrently poor platelet transfusion increment show human leukocyte antigen (HLA) alloantibodies. The aim of this study was to analyse the impact of mean fluorescence intensity (MFI) levels of donor‐specific HLA antibodies and the feasibility of the HLAMatchmaker algorithm in donor selection.
Keywords:
specific hla;
hla;
platelet donor;
donor selection;
donor specific
Journal Title: Transfusion Medicine
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Transfusion Medicine
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!